全文获取类型
收费全文 | 2734篇 |
免费 | 319篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 95篇 |
妇产科学 | 38篇 |
基础医学 | 243篇 |
口腔科学 | 111篇 |
临床医学 | 402篇 |
内科学 | 639篇 |
皮肤病学 | 46篇 |
神经病学 | 111篇 |
特种医学 | 336篇 |
外科学 | 232篇 |
综合类 | 39篇 |
一般理论 | 5篇 |
预防医学 | 459篇 |
眼科学 | 19篇 |
药学 | 120篇 |
2篇 | |
中国医学 | 3篇 |
肿瘤学 | 157篇 |
出版年
2023年 | 52篇 |
2022年 | 22篇 |
2021年 | 48篇 |
2020年 | 77篇 |
2019年 | 43篇 |
2018年 | 82篇 |
2017年 | 59篇 |
2016年 | 70篇 |
2015年 | 94篇 |
2014年 | 148篇 |
2013年 | 165篇 |
2012年 | 114篇 |
2011年 | 116篇 |
2010年 | 109篇 |
2009年 | 122篇 |
2008年 | 116篇 |
2007年 | 151篇 |
2006年 | 114篇 |
2005年 | 103篇 |
2004年 | 107篇 |
2003年 | 65篇 |
2002年 | 53篇 |
2001年 | 38篇 |
2000年 | 42篇 |
1999年 | 37篇 |
1998年 | 73篇 |
1997年 | 94篇 |
1996年 | 82篇 |
1995年 | 60篇 |
1994年 | 65篇 |
1993年 | 60篇 |
1992年 | 27篇 |
1991年 | 17篇 |
1990年 | 35篇 |
1989年 | 50篇 |
1988年 | 38篇 |
1987年 | 39篇 |
1986年 | 41篇 |
1985年 | 35篇 |
1984年 | 21篇 |
1983年 | 16篇 |
1982年 | 28篇 |
1981年 | 33篇 |
1980年 | 19篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 15篇 |
1976年 | 14篇 |
1975年 | 11篇 |
1966年 | 5篇 |
排序方式: 共有3076条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
65.
66.
67.
Since Ebola virus disease was identified in West Africa on March 23, 2014, the Centers for Disease Control and Prevention (CDC) has undertaken the most intensive response in the agency’s history; >3,000 staff have been involved, including >1,200 deployed to West Africa for >50,000 person workdays. Efforts have included supporting incident management systems in affected countries; mobilizing partners; and strengthening laboratory, epidemiology, contact investigation, health care infection control, communication, and border screening in West Africa, Nigeria, Mali, Senegal, and the United States. All efforts were undertaken as part of national and global response activities with many partner organizations. CDC was able to support community, national, and international health and public health staff to prevent an even worse event. The Ebola virus disease epidemic highlights the need to strengthen national and international systems to detect, respond to, and prevent the spread of future health threats. 相似文献
68.
69.
JD Roberts JC Herkert J Rutberg SM Nikkel ACP Wiesfeld D Dooijes RM Gow JP van Tintelen MH Gollob 《Clinical genetics》2013,83(5):452-456
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease that predominantly affects the right ventricle and is associated with ventricular arrhythmias that may lead to sudden cardiac death. Mutations within at least seven separate genes have been identified to cause ARVC, however a genetic culprit remains elusive in approximately 50% of cases. Although negative genetic testing may be secondary to pathogenic mutations within undiscovered genes, an alternative explanation may be the presence of large deletions or duplications involving known genes. These large copy number variants may not be detected with standard clinical genetic testing which is presently limited to direct DNA sequencing. We describe two cases of ARVC possessing large deletions involving plakophilin‐2 (PKP2) identified with microarray analysis and/or multiplex ligation‐dependent probe amplification (MLPA) that would have been classified as genotype negative with standard clinical genetic testing. A deletion of the entire coding region of PKP2 excluding exon 1 was identified in patient 1 and his son. In patient 2, MLPA analysis of PKP2 revealed deletion of the entire gene with subsequent microarray analysis demonstrating a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1. These findings support screening for large copy number variants in clinically suspected ARVC cases without clear disease causing mutations following initial sequencing analysis. 相似文献
70.
Stephanie R McKeown Paul Hatfield Robin JD Prestwich Richard E Shaffer Roger E Taylor 《The British journal of radiology》2015,88(1056)
Most radiotherapy (RT) involves the use of high doses (>50 Gy) to treat malignant disease. However, low to intermediate doses (approximately 3–50 Gy) can provide effective control of a number of benign conditions, ranging from inflammatory/proliferative disorders (e.g. Dupuytren''s disease, heterotopic ossification, keloid scarring, pigmented villonodular synovitis) to benign tumours (e.g. glomus tumours or juvenile nasopharyngeal angiofibromas). Current use in UK RT departments is very variable. This review identifies those benign diseases for which RT provides good control of symptoms with, for the most part, minimal side effects. However, exposure to radiation has the potential to cause a radiation-induced cancer (RIC) many years after treatment. The evidence for the magnitude of this risk comes from many disparate sources and is constrained by the small number of long-term studies in relevant clinical cohorts. This review considers the types of evidence available, i.e. theoretical models, phantom studies, epidemiological studies, long-term follow-up of cancer patients and those treated for benign disease, although many of the latter data pertain to treatments that are no longer used. Informative studies are summarized and considered in relation to the potential for development of a RIC in a range of key tissues (skin, brain etc.). Overall, the evidence suggests that the risks of cancer following RT for benign disease for currently advised protocols are small, especially in older patients. However, the balance of risk vs benefit needs to be considered in younger adults and especially if RT is being considered in adolescents or children. 相似文献